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Abstract
Background: At present, it is complicated to use screening trials to determine the optimal age
intervals and periodicities of breast cancer early detection. Mathematical models are an alternative
that has been widely used. The aim of this study was to estimate the effect of different breast cancer
early detection strategies in Catalonia (Spain), in terms of breast cancer mortality reduction (MR)
and years of life gained (YLG), using the stochastic models developed by Lee and Zelen (LZ).
Methods: We used the LZ model to estimate the cumulative probability of death for a cohort
exposed to different screening strategies after T  years of follow-up. We also obtained the
cumulative probability of death for a cohort with no screening. These probabilities were used to
estimate the possible breast cancer MR and YLG by age, period and cohort of birth. The inputs of
the model were: incidence of, mortality from and survival after breast cancer, mortality from other
causes, distribution of breast cancer stages at diagnosis and sensitivity of mammography. The
outputs were relative breast cancer MR and YLG.
Results: Relative breast cancer MR varied from 20% for biennial exams in the 50 to 69 age interval
to 30% for annual exams in the 40 to 74 age interval. When strategies differ in periodicity but not
in the age interval of exams, biennial screening achieved almost 80% of the annual screening MR. In
contrast to MR, the effect on YLG of extending screening from 69 to 74 years of age was smaller
than the effect of extending the screening from 50 to 45 or 40 years.
Conclusion: In this study we have obtained a measure of the effect of breast cancer screening in
terms of mortality and years of life gained. The Lee and Zelen mathematical models have been very
useful for assessing the impact of different modalities of early detection on MR and YLG in
Catalonia (Spain).
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Background
Randomized controlled trials (RCT) are the gold standard
for measuring medical interventions. Although controver-
sial, RCT assessing the effectiveness of screening with
mammography have provided valuable information
[1,2]. While there is still debate about the best screening
strategies, and what benefits they produce, at present the
cost, time, contamination issues and difficulties with
compliance preclude additional RCT for early detection of
breast cancer. Because statistical population trends are
affected by many factors and therefore are not accurate in
measuring the effect of health interventions, there has
been increased interest in using population data and
mathematical models to assess the effectiveness of early
breast cancer detection.
Mathematical models for assessing the effect of health
interventions are structured representations of health
states and the transitions between them. These models
may describe the relationship between an intervention
and changes in incidence and mortality rates for a specific
disease in a particular population. In the United States
(US), a consortium of researchers participating in the
Cancer Intervention and Surveillance Modeling Network
(CISNET) used statistical and simulation modeling to
quantify the relative impact of adjuvant therapy and
screening mammography on the decline of breast cancer
mortality [3,4]. The stochastic models that Sandra Lee and
Marvin Zelen designed in the US under CISNET are an
alternative to population trials for addressing and
responding to most of the questions that arise when
developing and assessing the effect of early detection [5-
10].
In Spain there is a National Health System (NHS),
financed primarily by taxes, which provides universal and
free health coverage, including early detection of breast
cancer. Catalonia is an autonomous region of Spain
which has approximately one sixth of the Spanish popu-
lation. By the year 2007, the Catalan Health Service was
providing services to seven million inhabitants, including
3.5 million women. The Catalan Breast Cancer Screening
Program (BCSP) started gradually, at the beginning of the
1990s, providing biennial mammography screening tests,
with the target population being women 50-64 years old.
Since the year 2000, women older than 64 are kept in the
program until the age of 69, based on the results of a
model-derived cost-effectiveness study published in 1998
[11]. At the present time, there is interest in assessing the
impact and cost-effectiveness of different modalities (age
at the first exam, number of exams and periodicity of
exams) of breast cancer early detection in Catalonia
(Spain).
The aim of this study was to estimate the effect of different
strategies of breast cancer early detection in Catalonia
(Spain), in terms of reduction of breast cancer mortality
and years of life gained, using the stochastic models devel-
oped by Lee and Zelen.
Methods
The Lee and Zelen's (LZ) model
Lee and Zelen developed a probabilistic model that pre-
dicts mortality as a function of the early detection modal-
ity. The characteristics and assumptions of the LZ model
are described in detail elsewhere [5-10]. The assumptions
of the LZ model (see Figure 1) are (1) a four-state progres-
sive disease in which a subject may be in a disease-free
state (S0), preclinical disease state (Sp: capable of being
diagnosed by a special exam), clinical state (Sc: diagnosis
by typical health care), and a death from breast cancer
state  ; (2) age-dependent transitions into the differ-
ent states; (3) age-dependent examination sensitivity; (4)
age-dependent sojourn times in each state; and (5) exam-
diagnosed cases have a stage-shift in the direction of more
favorable prognosis relative to the distribution of stages
with typical health care.
() Sd
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Health states and transitions in the Lee and Zelen's model. Figure 1
Health states and transitions in the Lee and Zelen's model.BMC Cancer 2009, 9:326 http://www.biomedcentral.com/1471-2407/9/326
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The LZ model considers:
￿  n  screening exams at times t0 <t1 < ... <tn-1. It is
assumed that t0 = 0 and age = z at t0 = 0.
￿ Three chronological times (see Figure 1):
- x: time at entering Sp, z + x: age when entering Sp.
The time x is not observed but can be derived from
the incidence function and the distribution of
sojourn time in the Sp state. x takes a negative value
if the transition to Sp occurs before the age at first
exam, z.
- : time at entering Sc, z +  : age at entering Sc. The
time  can not be observed in cases detected by
exam, only in the clinically detected cases. For
cases detected by exam,  can be estimated.
- y: time at death: x < <y
￿ Sojourn time in Sp:  - x
￿ Sojourn time in Sc: y - 
A very relevant element that the LZ models use is the con-
cept of an individual of generation j, which is defined as
an individual that enters the pre-clinical state at the jth
interval, (tj-1, tj). The formulas used to estimate the model
probabilities are based on this concept.
The LZ basic model calculates the cumulative probability
of death for the cohort group exposed to any screening
program after T years of follow-up. Similarly, the cumula-
tive probability of death for the cohort group having typ-
ical health care can be calculated. These probabilities are
used to calculate the possible reduction in mortality from
an early detection program after T years of follow-up.
Survival distributions for exam-diagnosed, interval, and
control cases are assumed to be conditional on the stage
at diagnosis and treatment, but are not dependent on the
mode of diagnosis. The LZ model assumes k stages, s(j),
i(j) and c(j) represent the probability of being diag-
nosed at stage j, j = 1,..., k for exam-diagnosed, interval
and control cases, respectively, and fj(t|z + ) is the proba-
bility density function (pdf) of survival time t among sub-
jects who would have been clinically diagnosed at stage j
in the absence of screening. Then the survival time pdfs of
the exam-diagnosed, interval and control cases are the
mixtures ,
 and
, respectively.
Since screening will appear to increase survival time, the
LZ model controls for lead time bias by setting the origin
of survival time for the screened, interval, and clinical
cases at the time of clinical diagnosis. Consequently, there
is an implied guarantee time for disease-specific survival,
that is, the cases diagnosed earlier would have been alive
at the time the disease would have been clinically diag-
nosed. This guarantee time, also called lead time, is a ran-
dom variable and is incorporated into the equations of
the model.
Explicitly, the lead time is  - tr where  is the time at which
the individual enters the clinical state and tr is the time at
which the r detection exam, when the disease will be diag-
nosed, is given.
The inputs of the Lee and Zelen's model for Catalonia
We studied women born during the calendar years 1930
to 1959. In this article we present results for the cohorts
born from 1955 to 1959. We assumed that the incidence
of breast cancer for ages younger than 25 years was insig-
nificant. When incidence or mortality data were not avail-
able, they were estimated using age-cohort models [12].
Incidence of breast cancer in Catalonia
Incidence data from the population-based cancer regis-
tries of the Catalan provinces Girona and Tarragona was
used. These two registries cover 20% of the Catalan popu-
lation. Data from the province of Girona was provided by
the Girona Cancer Registry and data from Tarragona was
downloaded from the International Agency for Research
on Cancer (IARC) [13]. The available periods with infor-
mation on breast cancer incidence were 1980-1989 and
1994-2002 for Girona and 1983-1997 for Tarragona. We
obtained the observed incidence rate by combining both
sources of information and using the population counts
of the official census for the same time periods [14]. To
model the data and obtain incidence estimates outside of
the observed calendar years we used a generalized linear
model with a Poisson distribution and polynomial para-
metrization of age and cohort variables [15]. This model
included a forth-degree polynomial for the age effects and
a second-degree polynomial for the cohort effects. Models
with lower degree terms for the age or cohort effects did
not fit the observed data properly.
Mortality due to causes other than breast cancer in Catalonia
We used the multi-decrement life table methodology to
partition overall mortality into mortality due to breast
gtz j ftz ss j j
k
(| ) () (| ) += +
= ∑ τφ τ
1
gtz j ftz ii j j
k
(| ) () (| ) += +
= ∑ τφ τ
1
gtz j ftz cc j j
k
(| ) () (| ) += +
= ∑ τφ τ
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cancer and mortality due to causes other than breast can-
cer [16]. Mortality data was obtained from the Catalan
Mortality Registry and the National Institute of Statistics
(INE) [14,17]. Overall mortality data was available for cal-
endar years 1900 to 2004 and breast cancer mortality data
was available for calendar years 1975-2004. Population
estimates were obtained from the INE and the Catalan
Statistics Institute (IDESCAT) [14,18]. We subtracted the
conditional probabilities of dying from breast cancer from
the overall conditional probabilities of death to obtain
the probabilities of dying from causes other than breast
cancer. We estimated the missing breast cancer mortality
probabilities for earlier years of birth using an age-cohort
model similar to the generalized linear model described
in the incidence data section. Details of these estimations
can be found elsewhere [19].
Distribution of stages at diagnosis
Since there was limited information in Catalonia on the
distribution of disease stages at diagnosis, we used the US
data. Lee and Zelen [7] reported the AJCC distributions of
stages for cases diagnosed without screening, screening-
detected cases and interval cases. The stage distribution for
cases without screening was provided by the Surveillance
Epidemiology and End Results (SEER) program of the
National Cancer Institute and the stage distribution for
the screen-detected and interval cases were provided by
the Breast Cancer Surveillance Consortium (BCSC). For
screen-detected cases and interval cases Lee and Zelen dis-
tinguish between annual, biennial and irregular screen-
ing. Details on stage distribution and definitions of
screen-detected or interval cases can be found in Lee and
Zelen's work.
Sensitivity of mammography
The sensitivity of mammography in our model was
assumed to be the following: 0.55 for < 40 years, 0.65 for
40 - 45 years, 0.70 for 45 - 50 years, 0.75 for 50 - 70 years
and 0.80 for  70 years. These values were used by Lee and
Zelen for screening exams conducted in 1995-2000, when
they estimated the impact of mammography and adjuvant
treatments in the US [7]. Lee and Zelen derived these data
from the BCSC database which contains mammogram
screening data and follow-up for approximately one mil-
lion US women starting from 1994.
Estimation of survival functions in Catalonia
Breast cancer survival data was not available, in Catalonia,
at the population level. We obtained breast cancer sur-
vival data from the Girona province Cancer Registry,
which covers an area of 700,000 inhabitants and repre-
sents approximately 10% of the Catalan population. Since
data from the Girona Registry was scarce, to obtain stable
estimates of the Catalan survival functions by age group
and disease extension, we derived the Catalan survival
time (pdfs) from survival data for the US in calendar years
1975-1979. First, based on the Girona Cancer Registry
and the US data, we estimated the hazard ratios for Girona
in the period 1980-1989 versus the US in the period 1975-
79, by AJCC disease stage. Both periods are considered
prior to the dissemination of screening mammography in
the respective countries and survival functions in these
periods are not affected by the lead time bias. Second, we
multiplied the estimated hazard ratios by the US hazard
rates, by age and stage of disease, and obtained an esti-
mate of the Catalan hazard functions for the 1980-1989
period. We assumed that survival data from the Girona
Cancer Registry is representative of Catalan breast cancer
survival. Fourth, we used the Catalan hazard functions to
obtain cumulative survival functions and survival time
pdfs.
If the hazard ratios of Girona versus the US were not pro-
portional over time, we estimated a time dependent haz-
ard ratio using the formula:
The Catalan cumulative survival functions, by stage of dis-
ease, obtained from the estimated hazard functions using
expression (1) fit the observed data from the Girona Can-
cer Registry well, based on the deviance statistic.
More details on how we obtained the Catalan breast can-
cer survival functions can be found elsewhere [20].
We used the same method to obtain estimates of the sur-
vival functions for the 1990-2001 period and we used
these functions to asses the impact of changing the sur-
vival functions in the effectiveness of early detection.
Since screening was prevalent in Catalonia during the
1990s, these survival functions are affected by the lead
time bias and overestimate survival time after breast can-
cer diagnosis. In this paper we used them as a very favour-
able scenario to compare with results obtained when
using the survival functions of the 1980s.
The application of Lee and Zelen's model to assess the 
effect of different breast cancer screening scenarios in 
Catalonia
Estimation of mortality for the not-screened group (control group)
Lee and Zelen [5] estimated Ic(y|z), the probability of
dying y years after the start of the study conditional on
being age z at time zero for the group receiving usual care
as:
log
hazard rateGirona
hazard rateUS
log time () * ( )
 
 
=+ ββ 01 (1)
Iy z i z gy z d c
y
c || () =+ ( ) −+ () ∫ ττ τ τ
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where i(z + ) is the age-specific point incidence function
for age z +  and gc(y - |z + ) is the survival time pdf of
control detected cases.
In the LZ model, the probability of disease-specific death,
for the control group, at age z + T can be estimated as:
And, the cumulative probability of disease-specific death, for
the control group, after T years of follow-up time can be
estimated as:
Estimation of mortality for the screened group
Mortality from cases detected in the screening exams
Lee and Zelen estimate the probability Dr(y|z) of being
diagnosed at the r exam (time tr) and dying y years after
the start of the study, where z is the age at the start of the
study. In order to obtain Dr(y|z) Lee and Zelen distinguish
two situations:
1. Being diagnosed at the first exam (t0, r = 0). In this
case the women had entered Sp before t0.
2. Being diagnosed at subsequent exams r = 1,... n - 1.
In this case there are three possible situations depend-
ing on cases:
(a) being at Sp before t0. All the previous screening
exams gave false negative results.
(b) entering Sp at a later time x after t0, but prior to the
exam r - 1 (time tr-1), (tj-1 <x  tj, j = 1, 2,..., r - 1, r > 1).
At least the exam r - 1 gave a false negative result.
(c) entering Sp at (tr-1, tr). No previous false negative
results.
The four situations cover all the possibilities of early
detection in a specific exam. Adding up the cumulative
probabilities of dying in any of these four situations, one
obtains the probability that a diagnosed case dies after y
years of having started the study:
Mortality from cases detected in intervals between exams
Similarly to cases detected by exams, one can estimate the
probability  Ir(y|z) of being diagnosed in the r  interval
between exams (tr-1, tr) and dying y years after the start of
the study.
Once the probabilities Ir(y|z) are estimated, the probabil-
ity that an interval case dies y years after the start of the
study is:
Combining both possibilities of detection, the probability
of disease-specific death for cases diagnosed in the early
detection program, at age z + T, can be estimated as:
And the cumulative probability of disease-specific death for
cases diagnosed in the early detection program, after T
years of follow-up time, is:
Measures of effect
Relative breast cancer mortality reduction (MR) up to a specific age
For a specific cohort , the breast cancer relative mortality
reduction up to age w, can be obtained using the expres-
sion:
In our analysis we have considered the upper limit of age
w to be 80 years. MR has been obtained from 40 to 80
years of age for the cohort.
Years of life gained (YLG) up to a specific age
To obtain the average number of years of life gained (Y
LG) attributable to screening, we subtracted the number
of years of life lost due to breast cancer with screening (Y
LL) from years of life lost without screening (YLL0). The
number of years lost have been computed as zero for the
proportion of women that survive up to 80 years of age,
and as the difference between 80 and the age at death (z +
y) for the proportion of women that die from breast can-
cer. Women that do not die from breast cancer are
assumed not to have lost any years of life. Thus, the YLG
up to age 80, have been estimated as:
with Ic(y|z), D(y|z) and I(y|z) defined as in the MR section.
dzT z Iy z d y c
T
T
0
1
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Then, YLG per woman screened have been estimated by
dividing the number of YLG by the proportion of women
surviving at age 40 in the Catalan population. Similarly,
YLG per breast cancer diagnosed have been estimated by
dividing YLG by the proportion of women with a diagno-
sis of breast cancer in the interval 40 to 80 years of age.
Sensitivity analysis
In order to assess the impact on mortality reduction of
changes in the input parameters, we varied the mammog-
raphy sensitivity and the survival time pdfs. We estimated
the impact of changing the sensitivity of mammography
by setting the initial sensitivities in the model to 90% for
all age groups. But, since changes in the sensitivity of
mammography may affect the distribution of stages at
diagnosis as well as the distribution of sojourn time in a
pre-clinical state, for which we do not have accurate data,
we present only data on the effect of changing the survival
time pdfs.
Results
Effect of early screening on mortality reduction (MR)
Table 1 presents the effect of early detection on breast can-
cer mortality MR (first column), in the 40 to 80 year age
interval, for cohorts born in the period 1955-59, with the
following assumptions: 1) screening started in 1985, 2)
all women in the target population participated in early
detection and 3) survival pdfs are the estimated Catalan
pdfs for the 1980-1989 period. Measures of effect were
obtained by comparing the screened cohort to a cohort
with the same characteristics, but without screening. In
Table 1 we show the data obtained with screening for the
age intervals 40-74, 40-69, 50-74 and 50-69, both with
annual and biennial mammography exams.
For annual screening in the 40-74, 45-74 and 50-74 age
intervals, the estimated MR were 29.8%, 28.9% and
27.4%, respectively. When annual screening was done in
the 40-69, 45-69 and 50-69 age intervals, the estimated
MR were 27.6%, 26.7% and 25.3%, respectively. When
strategies differ in periodicity but not in the age interval of
exams, biennial screening achieves almost 80% of the
annual screening MR. For example, annual exams in the
age interval 40-74 for women born in 1955-59 represent
a MR of 30%, whereas biennial exams in this age group
represent a 23% MR.
Effect of early screening on years of life gained (YLG)
Table 1 (second and third columns) presents the average
number of YLG per woman participating in early detec-
tion and per breast cancer detected, respectively, in the 40-
80 year age interval. Gains per woman screened range
from 0.13 years (48 days) for biennial exams in the 50-69
age interval to 0.22 years (80 days) for annual exams in
the 40-74 age interval. Gains per breast cancer detected
extend from 1.11 years for biennial exams in the 50-69
age interval to 1.87 years for annual exams in the 40-74
age interval. In contrast to MR, the effect on YLG of
extending screening from 69 to 74 years of age is much
smaller than the effect of extending the screening from 50
to 45 or 40 years.
Impact of changing the survival probability density 
functions (pdfs) on the estimated effect of early detection
Table 2 shows the effect on MR and YLG when different
survival pdfs are used. Results for annual exams in ages 40-
74 years and biennial exams in ages 50-69 years are pre-
sented. In scenario A we assumed that the survival time
pdfs were the 1980-1989 Catalan functions (pre-mam-
Table 1: Estimated effect of early breast cancer (BC) detection, in the 40-80 year age interval, with different screening strategies.
Periodicity Age interval for screening exams Effect of early detection
MR (%) YLG
per woman screened
YLG
per BC detected
Annual 40-74 29.8 0.222 1.874
Biennial 40-74 22.9 0.165 1.387
Annual 45-74 28.9 0.205 1.727
Biennial 45-74 22.3 0.152 1.283
Annual 50-74 27.4 0.180 1.515
Biennial 50-74 21.3 0.134 1.127
Annual 40-69 27.6 0.219 1.845
Biennial 40-69 21.2 0.162 1.369
Annual 45-69 26.7 0.201 1.697
Biennial 45-69 21.2 0.151 1.272
Annual 50-69 25.3 0.176 1.485
Biennial 50-69 19.6 0.132 1.109
Relative BC mortality reduction (MR) and Years of Life Gained (YLG). Catalonia, cohorts born in 1955-59.BMC Cancer 2009, 9:326 http://www.biomedcentral.com/1471-2407/9/326
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mography period). In scenario B we assumed an improve-
ment in survival was due to the utilization of adjuvant
treatments (hazard ratio of 0.75 with reference to the
1980-89 Catalan hazard rates). In scenario C we used the
Catalan survival pdfs for 1990-2001, which correspond to
the post-mammography-introduction period and overes-
timate survival because of the inclusion of the lead time.
Table 2 shows an improvement in mortality reduction for
both screening strategies when the survival functions
improve. If the hazard rates for women diagnosed with
breast cancer decrease to 75% of the 1980-89 hazard rates
(scenario B), MR would increase about 2 percentage
points. When using the 1990-2001 survival functions
(scenario C), MR increases dramatically, reaching values
of 44% for annual screening in the 40-74 age interval and
27.6% for biennial screening in the 50-69 age interval.
These values overestimate MR because of the lead time
bias, but show that the effect of early detection is influ-
enced by the survival distribution used in the model. The
higher the differences in survival between stage I and
stages II- and II+, the higher the reduction in mortality
attributable to screening.
When looking at the YLG between 40 and 80 years of age,
we did not see the same pattern as with MR (Table 2).
Contrary to what was expected, YLG per woman screened
or per breast cancer diagnosed remained similar or even
decreased when the survival functions improved. We
attribute this result to the fact that, when survival by stage
of disease improves, there is a gain in life-years in the no-
screening group, as well.
Discussion
Randomized clinical trials are important for assessing the
effects of screening. Nevertheless, the benefit of screening
for breast cancer has remained controversial because of
inconsistent results from clinical trials and controversies
in systematic reviews [1,2]. Mathematical models may
help answer questions for which empirical evidence is
scarce and aid in understanding some of the basic issues
relating to the early diagnosis of breast cancer [5]. We
have identified mathematical models which are very use-
ful for assessing the impact of different modalities of early
detection on reducing mortality and potential years of life
lost in Catalonia (Spain). Among the different approaches
to population modeling, we chose the Lee and Zelen
model because its assumptions are realistic and consistent
with other data sources [5,10]. The LZ model is flexible,
can incorporate complex information and interventions
and may be used to determine optimal screening modali-
ties.
Our aim was to assess the effect of different early detection
scenarios using data from Catalonia, when available. We
used Catalan population and mortality statistics. Breast
cancer incidence was estimated using data from Cancer
Registries in two Catalan provinces (Girona and Tarrag-
ona) and survival after a diagnosis of breast cancer was
obtained using data from one of the Catalan Cancer Reg-
istries (the Girona Cancer Registry) and the US survival
data. Incidence and mortality data for future time periods
was projected using age-cohort models. When regional
data was not available, we used information from the lit-
erature. We assumed that screening started in 1985, which
Table 2: Estimated effect of early detection of breast cancer (BC), in the 40-80 year age interval, with different BC survival scenarios. 
Scenario A Scenario B Scenario C
Interval of exams Annual Biennial Annual Biennial Annual Biennial
MR (%)
40-74 29.8 22.9 32.5 25.1 44.0 33.8
50-69 25.3 19.6 27.6 21.3 36.7 27.6
YLG per woman screened
40-74 0.222 0.165 0.203 0.151 0.208 0.154
50-69 0.176 0.132 0.161 0.120 0.162 0.119
YLG per breast cancer detected
40-74 1.874 1.387 1.711 1.272 1.753 1.300
50-69 1.485 1.109 1.353 1.010 1.367 1.003
Relative BC mortality reduction (MR) and years of life gained (YLG). Catalonia, cohorts born in 1955-59.
A: Survival probability density functions (pdfs): Catalonia 1980-1989 (pre-dissemination of mammography screening).
B: Resulting survival pdfs after applying a hazard ratio of 0.75 to the 1980-1989 hazard rates, in order to take into account the effect of adjuvant 
treatments.
C: Survival pdfs: Catalonia 1990-2001 (survival functions have not been corrected by the lead time bias that originates from earlier detection). This 
scenario produces an overestimation of the effect of early detection.BMC Cancer 2009, 9:326 http://www.biomedcentral.com/1471-2407/9/326
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is consistent with the fact that the Catalan Breast Cancer
Screening Program (BCSP) started gradually at the begin-
ning of the 1990s, but some opportunistic breast cancer
screening was done in the public and private health care
sector during the 1980s [21]. We also assumed that exams
started at 40 years of age or later and ceased at 69 or 74
years of age. In order to compare the effect of different
modalities of screening, we assessed the effect of different
screening scenarios in the same age span, 40-80 years of
age. Our results reflect the effect of early detection if all
women in each specific cohort had participated and com-
plied with the screening scenarios assessed.
Our findings
For all the studied birth cohorts, depending on the screen-
ing scenario, our estimated reduction in breast cancer
mortality in the 40-80 age span varied from about 20% for
biennial exams in the 50-69 age interval to about 30% for
annual exams in the 40-74 age interval. When exams were
performed biennially, the MR achieved was almost 80%
of the annual screening MR.
With annual exams, extending the program from 69 to 74
years produced mortality reductions roughly 2% higher,
whereas extending the program from 50 to 45 years pro-
duced increases of 1.5%. Extending from 45 to 40 years
represented an increase of 1% in mortality reduction. If
we look at the years of life gained, there were mimimal
changes when the program was extended from 69 to 74
years of age, whereas extending the program from 50 to 40
years of age increased the time gained per breast cancer
diagnosed by about 0.3 years (four months). In any case,
these results should be interpreted with caution, because
the impact of early detection also needs to take into
account the potential harm and cost of intensive screening
[22-24]. We have also observed that changes in breast can-
cer survival have an impact on the mortality reduction
achieved but not on the years of life gained.
Changes in the sensitivity of mammography to 90% sen-
sitivity in all age groups did not result in changes in MR or
YLG (data not shown). As we mentioned in the methods
section, an improvement in mammography sensitivity
may affect the distribution of the stages at diagnosis and
the distribution of sojourn time in a pre-clinical state.
Since we did not change these distributions, our assess-
ment of the impact of changing the sensitivity of mam-
mography may not fully reflect what would happen in
practice.
Comparison with other studies
Tabar et al, using data from the Regional Oncology Cen-
tres and Statistics Sweden for two Swedish counties
(Dalarna and Linkping), compared all deaths from breast
cancer diagnosed in the 20 years before screening was
introduced with those in the 20 years after introduction of
screening [25]. After adjustment for age, self-selection
bias, and changes in breast-cancer incidence in the 40-69
year age-group, Tabar et al estimated a 44% reduction in
breast cancer mortality in women exposed to screening
(RR = 0.56). They estimated a 16% reduction in women
not exposed to screening (RR = 0.84). The 33.3% ((0.84-
0.56)/0.84) difference in breast cancer mortality reduc-
tion between the screened and non-screened group can be
interpreted as the reduction attributable to screening. This
figure is higher than our estimated 21% reduction in the
40-69 year age-group with biennial exams, a scenario
comparable to the study of two Swedish counties where
the screening interval was 18 months for women in the
40-54 year age-group and two years in older women [26].
Similarly, the 39% reduction reported by the Swedish
Organised Service Screening Evaluation group, using data
from six counties with interscreening intervals of  two
years, is higher than our result for annual screening in the
40-69 year age interval [27,28].
Anderson et al assessed the impact of early detection in
Connecticut. They found that incidence rates for early-
stage tumors increased dramatically, whereas rates for
late-stage tumors experienced a modest decrease. Breast
cancer mortality rates fell 31.6%. These results were con-
sistent with effective early detection and improved treat-
ment over time, but also suggest that many
mammography-detected early-stage lesions may never
progress to late-stage cancers [29].
A Cochrane systematic review updated in 2006 by
Gotzsche and Nielsen, based on seven trials involving half
a million women in Europe and North America, esti-
mated a 15%-20% reduction in breast cancer mortality
[24]. These trials were conducted in the 1970s and the
1980s, and had different age intervals for exams and dif-
ferent periodicities. Most of the trials included women
aged 50 to 69 and the periodicity was variable; in most of
them screening was nearer to biennial exams than annual.
Reductions obtained using the LZ models with the Cata-
lan 1980-89 data are consistent with the results reported
in the Cochrane review.
Limitations and other considerations
We may have overstated the advantages of modelling and
the inability of RCT to answer some specific questions,
such as age at initiation and the ideal frequency of screen-
ing. It should be noted that many of the parameters used
in the models are obtained from the published RCT. In
fact, the models could also be seen as a form of sensitivity
analysis around health policy decision making. Models
can complement RCT by testing hypotheses that would be
impossible to test otherwise.BMC Cancer 2009, 9:326 http://www.biomedcentral.com/1471-2407/9/326
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The assumption that the distribution of breast cancer
stages at diagnosis was the same in Catalonia as in the US
may have slightly biased our results. We made this
assumption because information on the distribution of
stages for different screening patterns was not available in
Catalonia. We know that, before the introduction of
mammography, the distribution of stages in the GCR was
worse than in the US (41% localized, 49% regional and
10% distant stages in the GCR in the 1980-89 period ver-
sus 53% localized, 38% regional and 9% distant stages in
the US in the 1975-79 period). If we assume that the stage
distribution for different screening scenarios in Catalonia
is similar to the US distribution (which is consistent with
most of the RCT results, 70-80% of early diagnosed cases
which are node negative), then the stage shift attributable
to screening would have been even higher in Catalonia,
resulting in a larger effect of early detection. Therefore, the
assumption we made about the distribution of breast can-
cer stages at diagnosis may have resulted in a underestima-
tion of the effects.
We do not present a validation of our findings in this arti-
cle comparing the estimated effect of screening with
observed mortality data. Breast cancer mortality in the last
two decades has not only been influenced by the intro-
duction of mammography but also by other events like
the dissemination of adjuvant treatments. To validate our
findings we need to incorporate the dissemination of
mammography and adjuvant treatments, similar to what
the CISNET did in the US [3]. We are planning to do that
soon.
Several authors have reported a significant increase in
incidence attributable to screening [29,30]. We used an
age-period-cohort model to assess changes in incidence
trend related to the dissemination of screening. We found
a slight increase in incidence starting at the beginning of
the 1990s that did not reach statistical significance. As a
consequence, we projected breast cancer incidence using
an age-cohort model.
Gotzsche and Nielsen estimated a 30% increase in over-
diagnosis and overtreatment [24]. According to these
authors, for every 2000 women invited for screening
throughout 10 years, one will have her life prolonged and
10 healthy women, who would not have been diagnosed
if there had not been screening, will be diagnosed as
breast cancer patients and will be treated unnecessarily.
This study has not estimated the impact of false positive
results of early detection exams. We think that this is an
important issue to take into account when assessing the
effect of early detection. We are planning to extend the LZ
models to estimate the impact of false positive screening
results. Some authors have estimated that after 10 years of
annual screening, 30 to 50% of women have at least one
false-positive mammogram result [31-33]. In Catalonia,
Castells et al estimated that after 10 mammograms, the
cumulative false positive recall rate was 32.4% [34].
Finally, the ultimate goal of our project is to assess the
cost-effectiveness of different strategies for the early detec-
tion of breast cancer in Catalonia. In this study we have
obtained a measure of the effect of breast cancer screening
in terms of mortality and years of life gained. The impact
of false positives and a cost-effectiveness analysis using an
extension of the LZ models are our next targets.
Conclusion
We have estimated the impact of different strategies for
early detection, using mammography, on breast cancer
mortality reduction. For the first time our study presents a
measure of the effect of early detection based on the
observed Catalan incidence and breast cancer survival
data. Since it is currently difficult to use experimental
studies to determine optimal age intervals and periodici-
ties for screening, mathematical models are an alternative
for assessing the effects of early detection.
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